Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Tenets of PTEN tumor suppression.

Salmena L, Carracedo A, Pandolfi PP.

Cell. 2008 May 2;133(3):403-14. doi: 10.1016/j.cell.2008.04.013.

2.

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF.

Curr Cancer Drug Targets. 2008 May;8(3):187-98. Review.

PMID:
18473732
3.

PTEN: its deregulation and tumorigenesis.

Maehama T.

Biol Pharm Bull. 2007 Sep;30(9):1624-7. Review.

4.

The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.

Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N.

Genes Dev. 2006 Jun 15;20(12):1569-74.

5.

PTEN mutation: many birds with one stone in tumorigenesis.

Liu W, Zhou Y, Reske SN, Shen C.

Anticancer Res. 2008 Nov-Dec;28(6A):3613-9. Review.

6.

SnapShot: PTEN signaling pathways.

Carracedo A, Salmena L, Pandolfi PP.

Cell. 2008 May 2;133(3):550.e1. doi: 10.1016/j.cell.2008.04.023. No abstract available.

7.

The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer.

Assinder SJ, Dong Q, Kovacevic Z, Richardson DR.

Biochem J. 2009 Jan 15;417(2):411-21. doi: 10.1042/BJ20081610. Review.

PMID:
19099539
8.

Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast.

Cid VJ, Rodríguez-Escudero I, Andrés-Pons A, Romá-Mateo C, Gil A, den Hertog J, Molina M, Pulido R.

Oncogene. 2008 Sep 18;27(41):5431-42. doi: 10.1038/onc.2008.240. Review.

PMID:
18794878
9.

The PTEN-PI3K pathway: of feedbacks and cross-talks.

Carracedo A, Pandolfi PP.

Oncogene. 2008 Sep 18;27(41):5527-41. doi: 10.1038/onc.2008.247.

PMID:
18794886
10.

Post-translational regulation of PTEN.

Wang X, Jiang X.

Oncogene. 2008 Sep 18;27(41):5454-63. doi: 10.1038/onc.2008.242. Review.

PMID:
18794880
11.

PTEN in brain tumors.

Haas-Kogan D, Stokoe D.

Expert Rev Neurother. 2008 Apr;8(4):599-610. doi: 10.1586/14737175.8.4.599. Review.

PMID:
18416662
12.

PTEN level in tumor suppression: how much is too little?

Carracedo A, Alimonti A, Pandolfi PP.

Cancer Res. 2011 Feb 1;71(3):629-33. doi: 10.1158/0008-5472.CAN-10-2488. Epub 2011 Jan 25. Review.

13.

Genetic alterations in the PI3K pathway in prostate cancer.

Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G, Boyle P, Ohgaki H.

Anticancer Res. 2009 May;29(5):1739-43.

14.

The nuclear affairs of PTEN.

Planchon SM, Waite KA, Eng C.

J Cell Sci. 2008 Feb 1;121(Pt 3):249-53. doi: 10.1242/jcs.022459. Review.

15.

PTEN function: the long and the short of it.

Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE.

Trends Biochem Sci. 2014 Apr;39(4):183-90. doi: 10.1016/j.tibs.2014.02.006. Epub 2014 Mar 18. Review.

16.

Pills of PTEN? In and out for tumor suppression.

Papa A, Chen M, Pandolfi PP.

Cell Res. 2013 Oct;23(10):1155-6. doi: 10.1038/cr.2013.103. Epub 2013 Aug 6.

17.

Non-genomic loss of PTEN function in cancer: not in my genes.

Leslie NR, Foti M.

Trends Pharmacol Sci. 2011 Mar;32(3):131-40. doi: 10.1016/j.tips.2010.12.005. Epub 2011 Jan 13. Review.

PMID:
21236500
18.

The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy.

Malaney P, Uversky VN, Davé V.

Mol Biosyst. 2013 Nov;9(11):2877-88. doi: 10.1039/c3mb70267g.

PMID:
24056727
19.

In Cell and In Vitro Assays to Measure PTEN Ubiquitination.

Gupta A, Maccario H, Kriplani N, Leslie NR.

Methods Mol Biol. 2016;1388:155-65. doi: 10.1007/978-1-4939-3299-3_11.

PMID:
27033076
20.

Identification of nucleolus-localized PTEN and its function in regulating ribosome biogenesis.

Li P, Wang D, Li H, Yu Z, Chen X, Fang J.

Mol Biol Rep. 2014 Oct;41(10):6383-90. doi: 10.1007/s11033-014-3518-6. Epub 2014 Jun 27.

PMID:
24969487

Supplemental Content

Support Center